#694 Dexcom CEO chats from ADA 2022

June 4, 2022Scott Benner

Kevin Sayer chats about all things Dexcom with Scott.

You can always listen to the Juicebox Podcast here but the cool kids use: Apple Podcasts/iOS - Spotify - Amazon Music - Google Play/Android - iHeart Radio - Radio Public, Amazon Alexa or wherever they get audio.

+ Click for EPISODE TRANSCRIPT

DISCLAIMER: This text is the output of AI based transcribing from an audio recording. Although the transcription is largely accurate, in some cases it is incomplete or inaccurate due to inaudible passages or transcription errors and should not be treated as an authoritative record. Nothing that you read here constitutes advice medical or otherwise. Always consult with a healthcare professional before making changes to a healthcare plan.

Scott Benner 0:00
Hello friends and welcome to episode 694 of the Juicebox Podcast

well this won't happen very often on the podcast but this episode is as close as you may get to being live. Kevin Sayer who is the Dexcom CEO is on today. He is currently in New Orleans at the ADA meeting. Today is June 4, and this episode was just recorded. Please remember, while you're listening that nothing you hear on the Juicebox Podcast should be considered advice, medical or otherwise, always consult a physician before making any changes to your health care plan or becoming bold with insulin. If you're a US resident who has type one diabetes, or is the caregiver of someone with type one, please head over to t one D exchange.org. Forward slash juicebox. Join the registry. Take the survey, the whole thing takes fewer than 10 minutes. When you fill out that survey finish the survey. Your answers will have helped people living with type one diabetes, and at the same time you're supporting the Juicebox Podcast. If you want to try the diabetes pro tip episodes from the podcasts they begin at episode 210 In your podcast player, where you can find them at diabetes pro tip.com.

This show is sponsored today by the glucagon that my daughter carries G voc hypo Penn Find out more at G voc glucagon.com. Forward slash Juicebox. Podcast is also sponsored today by us med you can get your diabetes supplies easier and in a more convenient way than you're probably doing it right now by going to us med.com forward slash juice box or calling 888-721-1514 Hit that link or call that number and get yourself a free benefits check right now. See if you can't get started with us, Matt. I just like to jump right in. I know that you have things going on and things you'd like to share. I'd like to hear them. And then I have two questions at the end if you don't mind.

Kevin Sayer, Dexcom CEO 2:23
You know what? Fire away? You can ask me anything you want.

Scott Benner 2:26
Really? Do you want to do it? Now? My questions want

Kevin Sayer, Dexcom CEO 2:28
to answer everything you asked. But you can ask me anything you want.

Scott Benner 2:31
So my questions are? I mean, did you try to buy on the pod last week?

Kevin Sayer, Dexcom CEO 2:38
We issued a very public statement on Tuesday, after all the speculation that went on the week before that we're not acquiring or merging with anyone. We're here. We have our next comp plan sensing around the world. And and that's our plan. So okay, that's our answer.

Scott Benner 2:57
That's fine. I just I mean, I woke up one morning, everybody send me messages. What do you think of this? What do you do? I'm like, I don't know. What are you asking me for?

Kevin Sayer, Dexcom CEO 3:05
I got a few emails myself,

Scott Benner 3:07
I would imagine. I guess my other question is with libre three coming out? How do you see the two products? Do you see them as competitors now? Or do you? Because in the past, we've talked about that, that you don't see you didn't see the libre and the Dexcom as competitors. But are they getting closer?

Kevin Sayer, Dexcom CEO 3:26
Well, I think we are competitors. And I think that has really changed over time, particularly as both products have become more reimbursed and more mainstream. We're very comfortable with g7 is the premium product in the CGM category. As time goes on, we'll have an ICG designation upon approval will be integrated with the our partner systems as rapidly as we possibly can. We know our system performs spectacularly and we'll give our patients our customers they continue to experience they've had in the past. You know, the question everybody asked us way back in the day is could you make it smaller? Could you make it smaller? Could you make it smaller, we've reduced 60% of the size. From the G six this thing is a little bigger than a nickel and smaller than a quarter. And it is very, very easy to wear. And the performance of the system will speak for itself. It is incredibly well engineered. The manufacturing processes are very well baked out. You know for us operationally, one of the things about G seven that is different than anything we've done before, as we thought about how to build it before we designed it. This is a fully automated process. We couldn't build it manually if we had to, but this really is a fully automated process going from station to station. To the point where literally if, if there were a problem with the sensor, we can trace it all the way back to to all the manufacturing operations one by one with computer chip not with not with Uh, you know, warranty cards or something like that. So we have built a an incredible product with G seven and will compete with anybody. Again, we will have any ID designation, when we start our product, we'll have a 30 minute warmup not an hour warm up with 12 hours when you can't rely on the data. Okay, with a blood drop. So as far as system performance and features, we're very comfortable where

Scott Benner 5:23
we are, this is going to be a leap, is that a word you would use? A lot is seven, a leap from six?

Kevin Sayer, Dexcom CEO 5:29
Yeah, I think seven is a bigger leap from six than six was from five. Okay. All right. And if your users went from five to six, and I'm telling you seven is a bigger leap than six, you can understand why we're being rather cautious and, and planning as much as we can, because I think this is going to make a huge difference. Okay, lives of our users

Scott Benner 5:50
will, um, I don't want to ask you a bunch of g7 questions that you're telling me, I just wanted to just struck me will, will be covered by Medicaid, Medicare.

Kevin Sayer, Dexcom CEO 6:00
So the way there's a process for all these things got, and once we get approval, we'll go to every one of these agencies, we can and get approval as quickly as we possibly can. And the Medicare CMS process is typically 90 days, it may be longer just because of the government, but 90 days from approval, and then we have to go through all the Medicaid state by state as well. And their approval process varies depending upon where they distribute the product, is it through pharmacies or through DME? Suffice to say we have a great big map as to where we're gonna go and how quickly we're gonna go to get reimbursement for this as fast as we can for for our customers. Okay, so yeah, we're gonna go full on, let's get this thing approved everywhere, as quick as we can, once we get it approved at the FDA. So while

Scott Benner 6:50
we're talking about that, let me ask you, is there a roadmap to and how much are you involved in the idea that one day type twos might be prescribed CGM, as a matter of course, instead of something they have to fight about? Or pay out of pocket? Or Are we anywhere near that?

Kevin Sayer, Dexcom CEO 7:09
No, I love your question. And involved. It's an understatement. I think it is an obsession at this point in time. Every time we put our G six product on it, somebody on a group with type two diabetes in a study, we get incredible results. You saw the mobile trial with respect to Basal insulin, we had the same results with our Basal patients, as we get with the intensive insulin users in the diamond study, it was significant anyone see drops, because people change their lifestyle with proper information. We see the same with all the drugs. And as you look at the diabetes pie in the pie of diabetes costs in the future, there can be nothing more important than giving the health care providers and most of these type to patients see PCPs they're not endocrinologist yet. We're giving their health care providers simple, easy, easily accessible information to help dial in the proper drug for these patients to take and proper therapy for them to be on and enable to enable the lifestyle recommendations that come with that. So I think there's a day when it comes. I'd also tell you since I you know, we're just chatting about I also think that's a different problem than automated insulin delivery. And I think while the technology for measuring glucose the same, I think the patient experience will be much different. The app should be different, the software should be different, the pricing should be different, right? It's again, it's not solving serious a problem. Because that patient doesn't have the high and low, you know, danger zones that somebody like you and your family deal with.

Scott Benner 8:48
Or you're talking when you say you see a improvement for people, you're talking about type twos that don't use insulin seeing him Oh, absolutely. Okay. The reason the reason it got into my head was because very recently, my I have a Facebook group for the podcast, it has grown to over 25,000 people and it's starting to attract. Thank you. It's a wonderful tool for people and I love I love how well it helps them. But it's starting to attract insulin using type twos. And I'm beginning to have them on the podcast because they are having similar outcomes to the type ones who listened to the podcast. Oh, they do. Yeah, it's fascinating, actually. Yeah,

Kevin Sayer, Dexcom CEO 9:25
they do and and their outcomes are greatly enhanced if they could have got CGM earlier in the process as well. Yeah,

Scott Benner 9:34
no, I'm thinking of a couple of people specifically, just how it changed their life. Learning how to use insulin and how having Dexcom makes that so much.

Kevin Sayer, Dexcom CEO 9:44
I was in a I have. I have family up in Utah. And about a year and a half ago to Yeah, but year and half ago, we celebrated my dad's 86th birthday. And I had a cousin there I hadn't seen for a while. was 50 years, but she lived there. Obviously, we're not that close. But she came up to me at the party and she goes, she punched me in the arm. She goes, Hey, I need to talk to you. And here's what about she goes, You know, I have type two diabetes, I'm on insulin, and I got in a study with your sensor. I said, Well, how'd that go? And she said, Well, the study went me wearing one a month because they thought I can learn enough. With one a month, I could figure out how to change things. She goes, need to tell these people, that's a stupid idea. I need this all the time. I need it back. I need it all the time. Because she goes I I could make so many changes and do so much better. With this sensor on with this information, she goes, I have to have this full time. Right. And so that's, you know, and type two intensive insulin years are covered by Medicare, and covered by most of the commercial insurance plans. Now we've we've won a lot of those, those battles. And we have terrific coverage. Now for type two intensive, it's insulin users. You know, it's now our mission to continue down the chain and go to Basal insulin and get that approved and reimbursed for people and ultimately, some type of product offering an experience for those with type two diabetes who aren't on insulin because they can learn a tremendous amount and have a much healthier, longer life. Yeah,

Scott Benner 11:12
that's amazing. I, I somehow Imagine your whiteboard with your roadmap on it goes right off the board onto the wall

Kevin Sayer, Dexcom CEO 11:18
after a race and on a regular basis. That's because it's no i It's an obsession in our company. It really is.

Scott Benner 11:26
I appreciate it very much. All right. So you're down at Ada right now. And what are you there to tell people?

Kevin Sayer, Dexcom CEO 11:33
I am here to listen as much as I am to tell, I enjoy coming here to listen to what everybody perceives and what everybody has to say you learn much about your company and quite frankly, a CEO, I learn a lot about my people. I can do them because I don't I haven't we haven't been to a show in over two years. So I'm going to see people that I haven't met that worked that worked for us for two years. And that will be very fun. And a mess.

Scott Benner 12:02
Kevin, you're frozen

Kevin Sayer, Dexcom CEO 12:04
RG SIX sensor has never performed better. Our you know, our customer service. Our customer satisfaction data, both internal and external has never been higher. Our customer satisfaction data rivals, the biggest blue chip companies in the world. And and so we know we've done a lot of things, right. And we'll continue to do that. And I can occasionally get feedback on the end of things we can do better as well. So that that's why I'm here to hear and I'll meet with several physicians, many people I meet with our partners. I have a smattering of meetings across the board with a very, a great variety of people that affect our company. In the meantime, I spent some time with the folks that work for us too. So that's what I'll do here.

Scott Benner 12:52
That's excellent. I always people always asked me if I go and I'm like, I don't know what I would do there. But you made it sound like something I should do. You know

Kevin Sayer, Dexcom CEO 12:59
what? It's worth coming at least once. The other thing that's really fun is, for example, to walk the hall where the scientific posters are for somebody like us has been in this for so long. The Dexcom publications here are nothing short of remarkable. With respect to our product does. There's a study in Belgium, for example, that's been carried on for several years of patients who had a competitive CGM who switched over to Dexcom. And how much better they did after switching and how that improvement has been sustained. Supporting the true value of real time CGM vs. vs. other technologies. That poster is really fun for us. We've seen there's a lot of pediatric posters because people caring too much about pediatric some of the camps. For example, look, we put everybody in a camp on a sensor. And here's what we learned. All these posters are extremely good reading. And there's been a lot of thought going into them. And then the Scientific Sessions, the presentations, even the ones by the companies, there's a lot to learn from it, because we, obviously are going to put our best foot forward thing like this. And so you'll learn from those two, you'd enjoy going one Sunday, it'll be in your backyard. Again, you can go there.

Scott Benner 14:12
Yeah, I guess a little closer to me. I'll try it out. I just did you just the way he talks about I thought, oh, it's the first time I thought that sounds like something I'd want to do. I just didn't think I had a place at it prior. But it makes sense to me. Well, so are you there when you present? Do you talk about g7? I mean, is that the goal?

Kevin Sayer, Dexcom CEO 14:30
We're going to have a little bit of G seven but right now since g six is the commercially available product, most all the presentations are G six focused, you know we've we've published our g7 study data already. The g7 performance is much better than G six was in a very rigorous clear clinical trial setting. We have some talks about you know about some of the features and things but we're still all in with the technology that we have on the market. So a lot of the presentation Sims will refer to our automated insulin delivery partners as well. You know, Omni pod five is rolling out right now we're very excited about that launch. 10 continues to grow tremendously with with their product and the type zero algorithm that our team developed and licensed to them many years ago. So, you know, those will be a lot of our presentations, where a lot of that is this year, it's

Scott Benner 15:24
interesting. Arden's wearing of the Omnipod five right now, it's just put a lot a few days ago for the first time, so we're getting to know it. And it's been really interesting. So far, it's, it's what I what I took most from it, and I'm kind of excited about g7 to you sounds like g7 is going to be less user intensive, there's going to be less for you to do if that's even possible. But putting on on the pod five, coming off a loop. It just was, you know, it felt like you were just clicking screens, and and then you were there. So it was a that that to me, it was like the biggest you know, what

Kevin Sayer, Dexcom CEO 15:58
we've learned Scout over the years as complex, as long as complex is in the background. And it's great science that gives you a better experience. And that's a good thing complex for the users isn't good, right? And we've worked very hard to make g7 much more simple for somebody who start up and use you know, the half hour warm up. I I've had many people tell me those two hours without CGM data are the worst two hours of their of their weeks. Because you just sit there and you don't know that half hour is a big deal. And in fact it when you put one on it, usually it usually doesn't even take a half hour, it'll show up and say you got 25 or 26 minutes more that simplification and, you know, again, we've we've learned a lot. One other simplification, for example, we we've, if you've gone online with GTX, you've seen a whole bunch of overtype solutions people have invented or you call us and get RT we just put it over tape just gonna be some tape in the box

Scott Benner 17:00
I imagined to with the size and weight difference that's got to help to with just would just stay pinned. Yeah, right. So it how much smaller I know that that's not I mean, listen, I'm not complaining the G six is amazing and g7 is obviously smaller and form factor is there room to make these things smaller still.

You all know shorter episodes get shorter add. So get ready. These are going to be quick. US med here's what they have for you an A plus rating with the Better Business Bureau. They always provide 90 days worth of supplies, and they give you fast and free shipping. They carry everything from insulin pumps to diabetes testing supplies, and all the latest CGM like FreeStyle Libre two and the Dexcom G six, better service and better care if that's what you want. You go to us med.com forward slash juice box and get your free benefits check right now. You could also do it by phone at 888721151 for us med is the number one specialty distributor for Omnipod dash fastest growing tandem distributor nationwide. They're the number one distributor for FreeStyle Libre systems, the number one rated distributor index com customer satisfaction surveys and so much more. Check out us med right now us med.com forward slash juice box links in the show notes links at juicebox podcast.com. Or call 888-721-1514. When you have diabetes and use insulin, low blood sugar can happen when you don't expect it. GE voc hypo pen is a ready to use glucagon option that can treat very low blood sugar in adults and kids with diabetes ages two and above. Find out more go to G voc glucagon.com forward slash juicebox G voc shouldn't be used in patients with pheochromocytoma or insulinoma. Visit G voc glucagon.com/risk.

Kevin Sayer, Dexcom CEO 19:12
It's a very good question. And it's something we experiment with a lot when we went down to the g7 size it's 60% Smaller than G six. It's like I said it's smaller than a quarter. It's bigger than a nickel. We consider going smaller than that. But as you get into electronics and radio antennas and and how those things perform, there's a certain amount of size that optimize performance and that's why we settle on the size that we have. Okay, we have designs looking forward to it. Do we want smaller do we want thinner do we want more flexible? So in our advanced engineering group, we look at all sorts of answers for customers in the future. And on top of all that it has to be can can you build it too? Right? You know another interesting thing about G seven is just it It just all the manufacturing processes. It's the plastic the way it's put around the transmitter stuff, very complex for us to do leading to a great outcome. For.

Scott Benner 20:16
Kevin, you froze up there for a second. I'm

Kevin Sayer, Dexcom CEO 20:17
sorry, you say I'm sorry, great

Scott Benner 20:18
outcome. I

Kevin Sayer, Dexcom CEO 20:19
just got a message from my hotel that my internet was unstable. But we've not had a good internet, stay here at our at our hotel. But we'll get that figured out.

Scott Benner 20:31
I'll tell you what, the one thing you can do that I know from doing this so much is that take people who are around you while you're talking and get them off the Wi Fi? Because they pull from the signal. So anyway. Okay. Well, you, you don't have to I just know it works. But I'm sorry, you were saying leading to?

Kevin Sayer, Dexcom CEO 20:51
No, we were talking about size, and how small can you make these things, there also gets to be a size where their dexterity issues putting it on and off, you could almost go too small, I think. So we look at size, we look at features, we look at height versus diameter, because in all reality, the one of the other advantages of g7 is how much thinner it is. As far as not getting caught on things. I think, again, the experience will be and the work factor will be wonderful. But the simplicity of putting it on is literally I've got a box here in front of me. I mean, this is the box, size in my head and it you unscrew a cap at the bottom, put it on your body push, and then you're done. And then you pair it, it's you know, one of our one of our biggest opportunities, and some of you got much better at over the years of G six is explaining the transmitter and the transmitter. As you said, it's not that complicated. Not it's not that hard to use. But I also can't tell you how many people with their first sensor have peeled the transmitter off and thrown it away. Because they don't understand it. They have to use it again. We've eliminated that concern,

Scott Benner 22:02
right? No, I know that happens. I do know that people have the icy don't come online and they're in a panic, we throw out our G six transmitter, we don't know what to do bah bah bah. Now, just I mean, it's disposable, right? Yeah, fully disposable. You got it to 10 days right now.

Kevin Sayer, Dexcom CEO 22:20
We actually have 10 days with the 12 hour grace period. Okay.

Scott Benner 22:23
And do you think? Do you think that expands through software? Or do you think through the life of g7, it stays at 10.

Kevin Sayer, Dexcom CEO 22:30
I think over the life of g7, we're working on getting to 15. The issues with there are three ways we can make the sensor last longer we explore all three, one is the patch. And I'm sure you've had multiple patch postings on your, on your website and patch questions, we test all sorts of materials for patches. And if you make a patch, not sticky enough, that obviously falls off. But you also don't don't get allergic reaction. If you make it too sick, sticky, it may not fall off, but it may stay on too long. And so we've we evaluate patches for all those things, we believe we have a very good patch. In our current g7, we've got two or three more we're looking at to make patches last longer. The second piece of that is just sensor life in general, you know, when you put a sensor and you do create a wound, and eventually there's a wind response, and sometimes antibodies go around that. And that's why sometimes sensors failure, so fail. So what can we do to manage that. The third thing that we focus on is the algorithm and the data and the processing of the signal. So we have programs going in all three areas to make it last longer overriding all that, though, is again, the customer experience. Would you rather have something that last 15 days that 25% of them don't make it to the end, but it lasts 15 days? Or would you rather have something the last 10 days where 90 plus percent of them make it all the way through, we've learned that the the least satisfactory experience for one of our users is to have their last sensor of the month fail. And they haven't been able to come to the drugstore and get more because it failed early. So we really take that useful life seriously. To make that customer experience as best as we can. That's why we stayed at 10. Right now, that makes a lot of sense. But we look at ways to make it last longer.

Scott Benner 24:22
I'm going to ask you a question, if you don't mind about you come up with a product and then you have to test it on people and then I assume you you know, you have to get involved with the FDA. Show them what you've learned. What's the what's the life of that process? How long does that take from the day you start? No. Yeah,

Kevin Sayer, Dexcom CEO 24:41
we started g7 in 2017. Wow. Okay. And so that development process took a long time. Everything we do we do differently with G seven. We as a company and I don't think this is appreciated enough by the outside world. So I guess I'll stand on my soapbox for a minute. When we went to G six We had to write off all the equipment to produce G five, because we changed our manufacturing process entirely. We launched G six and G, we lost G six in 2018. And we were already developing another product that we knew would cause us to have to build all new manufacturing equipment and do it different. And we've made that investment, or we're making it, we, you know, all G six is manufactured on automated lines, we have some manual lines, if we need to up capacity, that equipment won't be applicable for g7. So we'll be phasing it out. And we'll be phasing it out. Because we have geographies where we still use G six, we have an organized, thoughtful manner for that. But we're making $100 billion over the next three years to get automated factories up and running for G seven G six processes, and getting ready to take these sensors everywhere. Our users will experience great satisfaction with this because we we've invested in taking that much time. So the FDA process and getting ready, I A doesn't take the whole five years. But the whole the time frame I'm telling you about for g7. So that's what it takes. And the other thing that has really changed from when I started in this business years ago, is that commitment to scale and spending for manufacturing. Before all these things were put together manually in our plant in San Diego, to get in this this business in to really serve customers is going to require a lot of money. And and I think we've been very thoughtful in doing that. But our commitment to the industry and to our customers is shown by our our investments.

Scott Benner 26:42
Yeah, no, I agree. Is does that mean that right now you're working on something that we'll see three, four or five years from now? Always, I guess that's the plan, right?

Kevin Sayer, Dexcom CEO 26:54
It's just and I think, as I look at our research efforts, I can break them down into really three buckets. One of them is software experiences, not only for our current users, but for also for our partners, and our partners, potentially, in the type two space or other entities, I think you're gonna see a number of software experiences from Dexcom over the years. And we just launched a version of G six in some international markets called Dexcom. One that is literally a G six, but a much less rigorous experience with respect to connectivity, being able to connect other devices, there's no share. And we are creating a two tiered product structure in these markets, where that is how it's reimbursed. So you'll see us create software experiences. So that's the first area the second is, you know, is sensors and modifying and enhancing the current product through better performance, new electronics, qualifying new suppliers, things of that nature. And then we have a third area where we go well, what is the future? Again, the wearable the what does it need to look like? How much smaller does it have to get how much smaller could you make it and still have the electronics performance that we need, but also future sensing capabilities, making it last longer things like that over in another group. So we spend our research dollars on all those things.

Scott Benner 28:17
It's funny, you said earlier about not making something so small that you can't handle it. And it popped into my head that I do an ad for a meter. That's a tiny meter that I like. And part of what I say while I'm talking about it is it's small, but not too small. And it never had never occurred to me the other way about about the sensor, but it does make sense, right? Your pupils dexterity comes into play at some point being able to handle the device, put it on, take it off. I don't know why that just popped back into my head. But that was a it was really something that I don't know, it just struck me at the time. So I mean, I always have to ask because if I don't, I'll get yelled at. But g7 will arrive just say the date out loud. I'm just kidding.

Kevin Sayer, Dexcom CEO 28:58
One of our policies is to never give a date. We'll update every bit and our progress. It has been submitted to the FDA, we're coming forth with the FDA right now. It's been a rigorous and a good process. We don't see anything that will prevent a launch of this product. And we're going to be as ready as we can I don't have a date for you now. We'll talk more about it publicly on our earnings call. But for today, G six is still the best option for everybody available.

Scott Benner 29:25
Do you produce products ahead of the the FDA saying go to make backlog or? Yeah, we do. Yeah.

Kevin Sayer, Dexcom CEO 29:33
But we're very careful about not producing too much in case we have to, for example, change some wording in the User Guide or something along those lines. So it's a it's it's definitely a balancing act. Yeah. For us. g7 is now approved for Europe. So we're building product for our launches in geographies in Europe over the second half of the year. Excuse me, and the fact is we build a number of this stuff as practice runs and And oftentimes throw away just to make sure everything is working build and test because we need to be ready to go. That's really

Scott Benner 30:07
amazing. Well, I appreciate all your efforts. Something happened recently where your your product was really, really important in my family's life so I appreciate it very much. Well,

Kevin Sayer, Dexcom CEO 30:19
Scott, we appreciate your commitment to Thanks for having me on the show again

Scott Benner 30:22
course enjoy the idea. Take care of by

a huge thank you to one of today's sponsors, GE voc glucagon, find out more about Chivo Capo pen at G Vogue glucagon.com forward slash juicebox you spell that GVOKEGLUC AG o n.com. Forward slash Juicebox. Podcast also going to thank us med for sponsoring this episode, and remind you to go to us med.com Ford slash juice box or call 888-721-1514. To get your free benefits check. Start getting your diabetes supplies in a way that doesn't make you want to run your head through a brick wall. There that's the tagline. If you're enjoying the Juicebox Podcast, please subscribe and follow in a podcast app. There are plenty of them. They are free. Apple podcast comes to mind Spotify, Amazon music, there's a whole bunch of them. If you don't know how to get to one, there's a whole bunch of them on my website juicebox podcast.com. I'd also like to suggest that you check out the private Facebook group for the podcast that was mentioned earlier. 25,000 members strong people just like you listening, learning, sharing commiserating hugging, it's everything you need it to be Juicebox Podcast, type one diabetes on Facebook, it's a private group, you'll have to answer a couple of questions to get in. But then you know you're around friends after that. I did mention the diabetes protests earlier. You can find them at juicebox podcast.com, or diabetes pro tip.com. And there's a ton of different series within the podcast not just the Pro Tip series. The easiest way to see them is probably to go to the Facebook page, the private one and go up to the feature tab. And in there there are these beautiful curated lists that show you all kinds of series with inside the podcast. I will go look at them for you right now. If you like Juicebox Podcast type one diabetes, featured tab at the top. So there's a list there about the Pro Tip series. There's a list there for the variable series different variables that impact your life with diabetes Quickstart episodes. What are some of the episodes people enjoy listening to? When they first get going with the podcast like episode 411 2937 There's a list of them there. I feel like I should have said hike after those numbers. Sorry, how we eat series. Some people eat vegan carnivore plant based gluten free low carb Bernstein FODMAP keto flexitarian intermittent fasting, we have episodes about all of that. There's the list of the most popular requested shows like talking about it. He's have allergies, Dexcom calibration practices. What do you have in your go bag? Advice for type one parents from type one adults? How could you help a newly diagnosed friend switching to an insulin pump? How do you split your long acting Basal insulin bolusing, insulin for fat, and all different kinds of stuff. These lists are right there in the feature tab. There's also a big series called ask Scott and Jenny. Jenny is a three decade long type one diabetic who's also a CTE. And she comes on the show all the time. So there's ask Scott and Jenny episodes where listeners send in questions and Jenny and I, we talk about them a whole list of how to Bolus for fat and protein. Oh, great couple of series about being pregnant with type one diabetes, defining thyroid so there's also a defining diabetes series. These are the terms that you'll use with diabetes, but there's also defining thyroid talking about things like hypo hyperthyroidism, Hashimotos pituitary glands, TSH, t 43, autoimmune goiter thyroiditis Graves disease, things you don't think about. But you might need to know about, about your thyroid care.

There's also a ton of episodes about algorithm pumping, looping on the pod five, control IQ and there are more and more of those coming every day. I really think you should subscribe. Go into your podcast app right now and hit subscribe or follow. That way you'll get all the new episodes right there for you. You get to pick through them and see what interests you. And don't forget the after dark series, drinking weed smoking, trauma and addiction. People having sex with type one diabetes, depression and self harm divorce and co parenting bipolar diet bulimia, heroin addiction. psychedelics. Oh my gosh, there's stuff here about I being the child of divorce, complications with diabetes, other eating disorders, other life struggles having diabetes for 50 years. There's one person on here talking about having ADHD, cocaine abuse. And very recently, a mother came on to talk about her son who she lost to addiction. These are all to do with type one diabetes and all available in the Juicebox Podcast, and the newest series. I love this new series. It's called type two stories. People with type two diabetes, come on to talk about their diabetes. Absolutely enlightening. Don't Don't miss it. I said that like there was no more but there's a mental wellness, a ton of mental wellness stuff with licensed marriage and family therapist, Erica Forsythe. She's also had type one diabetes for 30 years. We talked about all kinds of stuff about type one. Alright, I think that's all the series. I'm clicking through. It is that's it anyway, so you might see there is a ton of content inside of the Juicebox Podcast. It's all there for you. It's all free. Take it as you want. Use it as you will. I hope you enjoy it. I'll be back very soon with another episode of The Juicebox Podcast Subscribe and follow telephoned about the show